This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
MEI Pharma, Inc.
Drug Names(s): phenoxodiol
Description: Phenoxodiol is an inhibitor of NADH oxidase. Ultimately, this inhibition leads to blockage of the plasma membrane sphingomyelin pathway, inhibiting the production of the pro-survival secondary messenger, sphingosine-1- phosphate (S-1-P). Resistance to carboplatin is associated with increased S- 1-P levels, and the selective inhibition of production of S-1-P by phenoxodiol is believed to account for the ability of phenoxodiol to restore the sensitivity of tumor cells to carboplatin.
Deal Structure: Marshall Edwards has licensed rights from Novogen, its parent company, for Phenoxodiol.
In May 2011, Marshall Edwards announced the closing of the asset purchase agreement entered into between the Company and its majority shareholder, Novogen in December 2010. Under the agreement, Marshall Edwards acquires Novogen's isoflavone-based intellectual property portfolio in a stock-based transaction. Previously, Marshall Edwards licensed rights from Novogen for oncology drug candidates Phenoxodiol, Triphendiol, NV-143 and NV-128. Effective immediately, all prior licensing agreements between the two companies, including any potential future milestone or royalty payments, are canceled.
In June 2012, Marshall Edwards announced that it will change its name to MEI Pharma.
In July 2012, Novogen announced that it has entered into a merger agreement with Kai Medical. Novogen will be renamed to Kai Medical.
In addition to the merger agreement with Kai, Novogen announced that in advance...See full deal structure in Biomedtracker
Additional information available to subscribers only: